Substance Abuse Deterrents & Treatments Landscape Canvassed in In-demand CBR Pharma Insights Report Available at MarketPublishers.com
25 Apr 2016 • by Natalie Aster
LONDON – Substance abuse is turning into an increasingly pressing concern from pole to pole. The year 2012 saw an estimated 183,000 deaths related with drugs. The majority of deaths were recorded amid people making up the productive age cohort 15-64. Globally, close to 162 million – 324 million, aged 15-64, were suffering from substance and drug abuse. Though there are good drug products currently used to treat drug addiction, there remain areas were needs are yet to be filled.
An expanding treatment pipeline and ongoing research and investment in the domain highlight the fact that present-day therapies for those who have become victims of versatile drug addictions are still insufficient. Over 27 million people globally are currently categorised as problem drug users under the United Nations Office on Drugs and Crime's (UNODC) guidelines. Of these, only 1 in 6 has access to therapy, whilst a great many nations still have no decent services for the treatment of substance abuse.
The technologies that are utilised to mitigate the risk of Rx drug misuse and abuse are in relative nascency. Nevertheless, the market for abuse deterrent formulations (ADFs) is projected to gain increased traction in the years to come propelled by high demand and support from the local government across a great many leading markets.
In-demand research study “Substance Abuse Deterrents and Treatments - An Assessment of the Technological, Competitive and R&D Landscape” elaborated by CBR Pharma Insights provides an all-round, granular analysis of the current high unmet clinical needs and also an in-depth overview and examination of the technologies being exploited by pharmaceutical drug makers to minimise the risk of misuse and abuse of prescription drugs. It also presents a set of granular case studies showcasing novel ADFs that have been recently adopted by manufacturers of frequently abused prescription drugs. The report gives an insightful analysis and understanding of the market dynamics; an assessment of the products, marketed and pipeline, to treat substance addiction and abuse; insights into the present-day unmet clinical needs; review of the advancements in drug deterrent technology, their limitations and benefits; evaluation of the worldwide trends prevailing in the industry.
More studies by the publisher can be found at CBR Pharma Insights page.